Windward Bio AG

https://www.winwardbio.com

Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class TSLP monoclonal antibody into phase 2 development and creating novel, long-acting bispecific programs for immunological diseases. *

	Start	2024-06-20 established
	Industry	WIN378 (anti-TSLP monoclonal antibody)
	Industry 2	drug development
	Person	Santarelli, Luca (Windward Bio 202501 CEO + Co-Founder before VectivBio + Therachon + Roche)
	Person 2	D’Augusta, Claudia (VectivBio 202203 CFO formerly TiGenix 201204 CFO)

	Region	Basel BS
	Country	Switzerland
	Street	23 Seidentorstr. c/o Burckhardt AG
	City	4051 Basel
		Address record changed: 2025-01-11

Basic data	Employees	n. a.

		* Document for »About Section«: Windward Bio AG. (1/10/25). "Press Release: Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD". Basel.

		Record changed: 2025-03-16

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Windward Bio AG

[1] Windward Bio AG. (1/10/25). "Press Release: Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]